Hologic — Jul 29, 2024 release

We are on track for a strong finish to fiscal 2024.” Hologic’s financial guidance for the fourth quarter and full year 2024 is shown in the table below. The guidance is based on a full year non-GAAP tax rate of approximately 19.75%, and diluted shares outstanding of approximately 238 million for the full year. Constant currency guidance assumes that foreign exchange rates are the same in fiscal 2024 as in fiscal 2023. Organic revenue guidance for fiscal 2024 is in constant currency and excludes the divested Blood Screening, SSI ultrasound imaging, and Endomagnetics businesses. Revenue from acquired businesses is generally included in organic revenue guidance starting a year after the acquisition. Organic revenue excluding COVID-19 is in constant currency and is organic revenue excluding COVID-19 assay revenue, COVID-19 related revenue, and discontinued product sales in Diagnostics.   Current Guidance* Previous Guidance   Guidance $ Reported % Increase (Decrease) Constant Currency % Increase (Decrease) Organic excluding COVID-19 % Increase Guidance $ Fiscal 2024           Revenue $4,012 - $4,027 (0.4%) to (0.1%) (0.5%) to (0.1%) 5.2% to 5.6% $4,000 - $4,050 GAAP EPS $3.37 - $3.44 84.2% to 88.0%     $3.45 - $3.55 Non-GAAP EPS $4.04 - $4.11 2.0% to 3.8%     $4.02 - $4.12